Drugs Made In America Acquisition Corp（DMAA）股票分析

AI 分析 of Drugs Made In America Acquisition Corp (DMAA)

持有

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.

估值指标

Drugs Made In America Acquisition Corp（DMAA）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。

预期市盈率

严重低估

5 年均值 P/E

0.00

当前P/E

0.00

高估

0.00

低估

0.00

预期 EV/EBITDA

严重低估

5 年均值 EV/EBITDA

0.00

当前EV/EBITDA

0.00

高估

0.00

低估

0.00

预期市销率

合理

5 年均值 P/S

0.11

当前P/S

0.00

高估

1.18

低估

-0.96

Alphio AI 对 DMAA 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%DMAA

$10.91

情景价格

基

基准

基准 · 50%DMAA

$9.82

情景价格

悲

悲观

悲观 · 25%DMAA

$9.57

情景价格

持有 DMAA 的大户

G

Glazer Capital, LLC

+ 持有DMAA

+3.19%

3个月收益率

W

Wolverine Asset Management, LLC

+ 持有DMAA

-16.12%

3个月收益率

DMAA 常见问题 —— 由 Alphio AI 解答

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector.

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.